Speakers

Expand/Collapse

Hans-Peter Gerber
CEO & CSO
3T Biosciences

Day One

Wednesday, April 21st 2021

5:15 pm | Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

Focus Day

2:50 pm | Designing Best in Class TCR Cell Therapies Against Novel Antigens

Wigard Kloosterman
CSO
Frame Cancer Therapeutics

Day One

Wednesday, April 21st 2021

8:45 am | Whole Framome Cancer vaccination

Raymond Miller
Senior Global Product Manager, Therapeutic Materials
GenScript Biotech Corporation

Track A - Day 1 AM

12:15 pm | Using Predictive Bioinformatics Algorithms to Determine Neoantigen Peptide Synthesis Difficulty & Subsequent Production Methodology

Gerben Zondag
CEO
Immunetune

Track B - Day 1 AM

11:15 am | Development of an optimized platform for production and efficacy of personalized DNA vaccines

Wim Van Criekinge
CSO
myNeo

Track A - Day 1 AM

11:45 am | Past and future developments in the use of AI heuristics for successful neoantigen prediction

Elisa Scarselli
CSO and Co-founder
Nouscom

Day Two

Thursday, April 22nd 2021

9:30 am | Panel Discussion: Evaluating Combination Therapies

9:00 am | Nouscom Viral Vectored Vaccines Encoding Many Neoantigens Synergize With Immunotherapies Reverting Tumour Immune Suppression

Trevor Clancy
CSO & Co-founder
OncoImmunity

Day One

Wednesday, April 21st 2021

9:45 am | An Integrated Machine-Learning Approach to Improve the Prediction of Clinically Relevant Neoantigens

Russell Pachynski
Assistant Professor, Division of Oncology
Washington University School of Medicine

Track B - Day 2 AM

11:30 am | Designing the Right Clinical Trial for a Neoantigen Platform

Sara Mangsbo
Associate Professor
Uppsala University Sweden

Track B - Day 1 AM

12:15 pm | Towards a Flexible Peptide Based Delivery Platform for data-driven Personalized Cancer Therapy

Heinz Lubenau
Chief Operating Officer & Co-Founder
Vaximm

Day Two

Thursday, April 22nd 2021

9:30 am | Panel Discussion: Evaluating Combination Therapies

Track B - Day 2 AM

12:00 pm | Entering clinical trials with a personalized oral bacteria-based DNA vaccine - Overcoming hurdles and challenges

Eniko R Toke
Chief Scientific Officer
Treos Bio

Day One

Wednesday, April 21st 2021

9:15 am | A Personal Antigen Selection Calculator (PASCal) for the Design of Off-The-Shelf, Shared Neoantigen-Based Personal Vaccines

Focus Day

12:10 pm | Computational Design of a Global Peptide-based COVID-19 vaccine for Variable Viral Strains and Variable Human Genetics

Scott Burkholz
Bioinformatics Scientist
Flow Pharma, Inc.

 

Focus Day

2:20 pm | FLOVID-20: A Targeted T-cell Immunotherapy for COVID-19 using a Nebulizer

Track A - Day 1 PM

3:15 pm | FlowVax: A Synthetic, Adjuvanted Microsphere Peptide Vaccine Platform

Sari Pesonen
Head of R&D
Valo Therapeutics

Track B - Day 1 AM

11:45 am | Leveraging Onocolytic Viruses to Develop a Flexible Neoantigen Delivery Platform

Geoffrey Lynn
CEO
Avidea Technologies

Track B - Day 1 PM

1:45 pm | Intravenous vaccination improves cancer treatment efficacy

Gregory Potts
Senior Scientist
Abbvie

Track A - Day 1 PM

2:15 pm | Disease-specific Immunopeptides for Generation of Soluble TCR Therapies

Tom Whitehead
Co-Founder
Emily Whitehead Foundation

Day Two

Thursday, April 22nd 2021

3:30 pm | Journey to CAR T-cell Therapy

Gunnstein Norheim
Director, Infectious Disease
Vaccibody

Focus Day

11:40 am | Leveraging the experience from development of individualized cancer vaccines to vaccines against infectious diseases, including pandemics using the Vaccibody platform technology

Eric Halioua
President & CEO
PDC*line Pharma

Day One

Wednesday, April 21st 2021

5:15 pm | Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

Day Two

Thursday, April 22nd 2021

9:30 am | Panel Discussion: Evaluating Combination Therapies

Eric Quemeneur
CSO
Transgene

Day Two

Thursday, April 22nd 2021

2:00 pm | TG4050 : Viral immunotherapy meets AI technology

Hans-Peter Gerber
CEO & CSO
3T Biosciences

Melanie Patterson
Principal Research Scientist II
Abbvie

Maren Lang
Head of Bioinformatics Research & Development
BioNTech SE

Jens Kringelum
Director, Genomic Immuno-Oncology
Exaxion Biotech

Hubert Lam
Director, Pre-clinical Development
Genocea

Day Two

Thursday, April 22nd 2021

2:30 pm | The Impact of Stimulatory and Inhibitory Neoantigens Selected with the ATLAS Bioassay: Clinical and Pre- Clinical Results

Pranay Khare
Director, Cell Therapy Development & Manufacturing
Genocea Biosciences

Track B - Day 2 AM

12:30 pm | Key Considerations & Strategies for Technical Development of Personalised Neoantigen-based Cancer Vaccine and T-Cell Therapy

Jennie Lill
Executive Director of Proteomics & NGS
Genentech

Andrew Allen
CEO
Gritstone

Day One

Wednesday, April 21st 2021

5:15 pm | Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic

4:45 pm | Personalised Neoantigen Immunotherapy – Demonstrating Priming of CD8+ T cell Responses is a Key Step

Track B - Day 1 PM

3:15 pm | Does the Exquisite Tumor-Specificity of Neoantigens Render them Excellent Targets for Bispecific Antibody Therapy of Solid Tumors?

Alex Karlsson-Parra
CSO
Immunicum

Track B - Day 1 PM

2:45 pm | Harnessing the immune-priming function of allogeneic dendritic cells in neoantigen-based vaccines

Lei Zheng
Associate Professor
John Hopkins School of Medicine

Track A - Day 1 PM

1:45 pm | Identify HLA Class I and Class II specific TCRs in Pancreatic Cancer for Individualized T Cell Therapy

Alexandre Harari
Group leader, Department of oncology UNIL CHUV
Ludwig Institute for Cancer Research Lausanne

Track A - Day 2 AM

11:30 am | High-affinity Neoepitope-Specific T Cells Accumulate in Tumours

Pia Kvistborg
Junior group leader, Department of Immunology
The Netherlands Cancer Institute

Philip Arlen
CEO & CMO
Precision Biologics

Track B - Day 1 PM

2:15 pm | Developing Novel Antibodies to Targeting Tumour Neoepitopes

Kaidre Bendjama
Project Leader, Personalized Cancer Vaccines
Transgene

Nicola Ternette
Head of Immunopeptidomics
University of Oxford

Track A - Day 1 AM

11:15 am | Driving Antigen Discovery in Cervical Cancer

Agnete Fredriksen
President & Chief Scientific Officer
Vaccibody

Day Two

Thursday, April 22nd 2021

10:30 am | Targeting antigens to antigen presenting cells induce effective anti-tumor efficacy as monotherapy and as combination therapy

Alena Gros
Principal Investigator, Tumor Immunology & Immunotherapy
Vall d’Hebron Institute of Oncology (V.H.I.O)

Kostas Kosmatopoulos
CEO
Vaxon Biotech

Track A - Day 2 AM

12:30 pm | Are Immunogenic Tumours the Best Targets of Tumour Vaccination?

Randy Sweiss
Assistant Professor
University of Chicago

Day Two

Thursday, April 22nd 2021

3:00 pm | Multi-step Screening of Neoantigens’ HLA- and TCR-interfaces Improves Prediction of Survival in Urothelial Bladder Cancer

Anne De Groot
CEO/ CSO
EpiVax, Inc

Maik Pruess
Senior Field Applications Scientist
Personalis

Day One

Wednesday, April 21st 2021

4:15 pm | Personalis® NeXT Platform® for High-Accuracy Neoantigen Prediction, Composite Biomarker Identification and Personalized Cancer Therapy Development

Christopher Rose
Senior Scientist - Discovery Proteomics
Genentech Inc

Track A - Day 2 AM

12:00 pm | Characterizing Epitopes for Cancer Vaccines and T Cell Therapeutics

Alastair Hay
Head of Peptide Business and Process Development
Almac Sciences

Track B - Day 1 PM

3:45 pm | Challenges in Peptide Manufacture Supporting Neoantigen-Derived Cancer Vaccines and How to Overcome Them

Courtney Cambouris
NGS specialist – Sales manager
Pathoquest

Track A - Day 1 PM

3:45 pm | High throughput sequencing solutions for the quality control of innovative therapies

Cedric Bogaert
Chief Executive Officer
myNeo

Day Two

Thursday, April 22nd 2021

10:00 am | Extrapolation of epitope prediction from IO onto infectious diseases (lessons learned)